SIRT3 and cancer: Tumor promoter or suppressor?

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1816, Issue 1, 2011, Pages 80-88

  Alhazzazi, Turki Y ^a   Kamarajan, Pachiyappan ^a   Verdin, Eric ^b   Kapila, Yvonne L ^a  

^a UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; SIRT3; Sirtuin 3; Tumor promoter; Tumor suppressor

Indexed keywords

ANTINEOPLASTIC AGENT; CAMBINOL; ETOPOSIDE; HISTONE DEACETYLASE INHIBITOR; KAEMPFEROL; PHENYLACETIC ACID; RESVERATROL; SHORT HAIRPIN RNA; SIRTINOL; SIRTUIN 1; SIRTUIN 2; SIRTUIN 3; SIRTUIN 4; SIRTUIN 5; SIRTUIN 6; SIRTUIN 7; SPLITOMICIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; CARCINOGENESIS; CELL DEATH; CELL METABOLISM; CELL SURVIVAL; CELLULAR DISTRIBUTION; COLORECTAL CARCINOMA; DRUG CYTOTOXICITY; DRUG MEGADOSE; DRUG TARGETING; DRUG TOLERABILITY; GLIOBLASTOMA; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA; LOW DRUG DOSE; MOUTH CARCINOMA; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; RNA INTERFERENCE; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR PROMOTION; UNSPECIFIED SIDE EFFECT;

ANIMALS; APOPTOSIS; CELL SURVIVAL; ENERGY METABOLISM; HUMANS; NEOPLASMS; SIRTUIN 3;

MAMMALIA;

EID: 79957441575     PISSN: 0304419X     EISSN: 0304419X     Source Type: Journal    
DOI: 10.1016/j.bbcan.2011.04.004     Document Type: Review

References (131)

1. Minino A.M., Xu J., Kochanek K.D., Tejada-Vera B. Death in the United States, 2007. NCHS Data Brief 2009, 1-8.
2. Workman P., de Bono J. Targeted therapeutics for cancer treatment: major progress towards personalised molecular medicine. Curr. Opin. Pharmacol. 2008, 8:359-362.
3. Saunders L.R., Verdin E. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene 2007, 26:5489-5504.
4. Michan S., Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem. J. 2007, 404:1-13.
5. Frye R.A. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem. Biophys. Res. Commun. 2000, 273:793-798.
6. Haigis M.C., Guarente L.P. Mammalian sirtuins-emerging roles in physiology, aging, and calorie restriction. Genes Dev. 2006, 20:2913-2921.
7. Michishita E., Park J.Y., Burneskis J.M., Barrett J.C., Horikawa I. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol. Biol. Cell 2005, 16:4623-4635.
8. Luo J., Nikolaev A.Y., Imai S., Chen D., Su F., Shiloh A., Guarente L., Gu W. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001, 107:137-148.
9. Vaziri H., Dessain S.K., Ng Eaton E., Imai S.I., Frye R.A., Pandita T.K., Guarente L., Weinberg R.A. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001, 107:149-159.
10. Brunet A., Sweeney L.B., Sturgill J.F., Chua K.F., Greer P.L., Lin Y., Tran H., Ross S.E., Mostoslavsky R., Cohen H.Y., Hu L.S., Cheng H.L., Jedrychowski M.P., Gygi S.P., Sinclair D.A., Alt F.W., Greenberg M.E. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004, 303:2011-2015.
11. Cohen H.Y., Miller C., Bitterman K.J., Wall N.R., Hekking B., Kessler B., Howitz K.T., Gorospe M., de Cabo R., Sinclair D.A. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004, 305:390-392.
12. Huffman D.M., Grizzle W.E., Bamman M.M., Kim J.S., Eltoum I.A., Elgavish A., Nagy T.R. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res. 2007, 67:6612-6618.
13. Ota H., Akishita M., Eto M., Iijima K., Kaneki M., Ouchi Y. Sirt1 modulates premature senescence-like phenotype in human endothelial cells. J. Mol. Cell. Cardiol. 2007, 43:571-579.
14. Stunkel W., Peh B.K., Tan Y.C., Nayagam V.M., Wang X., Salto-Tellez M., Ni B., Entzeroth M., Wood J. Function of the SIRT1 protein deacetylase in cancer. Biotechnol. J. 2007, 2:1360-1368.
15. Sun Y., Sun D., Li F., Tian L., Li C., Li L., Lin R., Wang S. Downregulation of Sirt1 by antisense oligonucleotides induces apoptosis and enhances radiation sensitization in A549 lung cancer cells. Lung Cancer 2007, 58:21-29.
16. Hida Y., Kubo Y., Murao K., Arase S. Strong expression of a longevity-related protein, SIRT1, in Bowen's disease. Arch. Dermatol. Res. 2007, 299:103-106.
17. Potente M., Dimmeler S. Emerging roles of SIRT1 in vascular endothelial homeostasis. Cell Cycle 2008, 7:2117-2122.
18. Gao F., Cheng J., Shi T., Yeh E.T. Neddylation of a breast cancer-associated protein recruits a class III histone deacetylase that represses NFkappaB-dependent transcription. Nat. Cell Biol. 2006, 8:1171-1177.
19. Wang R.H., Sengupta K., Li C., Kim H.S., Cao L., Xiao C., Kim S., Xu X., Zheng Y., Chilton B., Jia R., Zheng Z.M., Appella E., Wang X.W., Ried T., Deng C.X. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 2008, 14:312-323.
20. Fu M., Liu M., Sauve A.A., Jiao X., Zhang X., Wu X., Powell M.J., Yang T., Gu W., Avantaggiati M.L., Pattabiraman N., Pestell T.G., Wang F., Quong A.A., Wang C., Pestell R.G. Hormonal control of androgen receptor function through SIRT1. Mol. Cell. Biol. 2006, 26:8122-8135.
21. Deng C.X. SIRT1, is it a tumor promoter or tumor suppressor?. Int. J. Biol. Sci. 2009, 5:147-152.
22. +-dependent tubulin deacetylase. Mol. Cell 2003, 11:437-444.
23. Dryden S.C., Nahhas F.A., Nowak J.E., Goustin A.S., Tainsky M.A. Role for human SIRT2 NAD-dependent deacetylase activity in control of mitotic exit in the cell cycle. Mol. Cell. Biol. 2003, 23:3173-3185.
24. Hiratsuka M., Inoue T., Toda T., Kimura N., Shirayoshi Y., Kamitani H., Watanabe T., Ohama E., Tahimic C.G., Kurimasa A., Oshimura M. Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. Biochem. Biophys. Res. Commun. 2003, 309:558-566.
25. Mahlknecht U., Ho A.D., Voelter-Mahlknecht S. Chromosomal organization and fluorescence in situ hybridization of the human Sirtuin 6 gene. Int. J. Oncol. 2006, 28:447-456.
26. Mostoslavsky R., Chua K.F., Lombard D.B., Pang W.W., Fischer M.R., Gellon L., Liu P., Mostoslavsky G., Franco S., Murphy M.M., Mills K.D., Patel P., Hsu J.T., Hong A.L., Ford E., Cheng H.L., Kennedy C., Nunez N., Bronson R., Frendewey D., Auerbach W., Valenzuela D., Karow M., Hottiger M.O., Hursting S., Barrett J.C., Guarente L., Mulligan R., Demple B., Yancopoulos G.D., Alt F.W. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 2006, 124:315-329.
27. Lombard D.B., Schwer B., Alt F.W., Mostoslavsky R. SIRT6 in DNA repair, metabolism and ageing. J. Intern. Med. 2008, 263:128-141.
28. Ford E., Voit R., Liszt G., Magin C., Grummt I., Guarente L. Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription. Genes Dev. 2006, 20:1075-1080.
29. Voelter-Mahlknecht S., Letzel S., Mahlknecht U. Fluorescence in situ hybridization and chromosomal organization of the human Sirtuin 7 gene. Int. J. Oncol. 2006, 28:899-908.
30. Ashraf N., Zino S., Macintyre A., Kingsmore D., Payne A.P., George W.D., Shiels P.G. Altered sirtuin expression is associated with node-positive breast cancer. Br. J. Cancer 2006, 95:1056-1061.
31. Frye R. "SIRT8" expressed in thyroid cancer is actually SIRT7. Br. J. Cancer 2002, 87:1479.
32. de Nigris F., Cerutti J., Morelli C., Califano D., Chiariotti L., Viglietto G., Santelli G., Fusco A. Isolation of a SIR-like gene, SIR-T8, that is overexpressed in thyroid carcinoma cell lines and tissues. Br. J. Cancer 2002, 86:917-923.
33. Huang J.Y., Hirschey M.D., Shimazu T., Ho L., Verdin E. Mitochondrial sirtuins. Biochim. Biophys. Acta 2010, 1804:1645-1651.
34. Haigis M.C., Mostoslavsky R., Haigis K.M., Fahie K., Christodoulou D.C., Murphy A.J., Valenzuela D.M., Yancopoulos G.D., Karow M., Blander G., Wolberger C., Prolla T.A., Weindruch R., Alt F.W., Guarente L. SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell 2006, 126:941-954.
35. Ahuja N., Schwer B., Carobbio S., Waltregny D., North B.J., Castronovo V., Maechler P., Verdin E. Regulation of insulin secretion by SIRT4, a mitochondrial ADP-ribosyltransferase. J. Biol. Chem. 2007, 282:33583-33592.
36. Argmann C., Auwerx J. Insulin secretion: SIRT4 gets in on the act. Cell 2006, 126:837-839.
37. Verdin E., Dequiedt F., Fischle W., Frye R., Marshall B., North B. Measurement of mammalian histone deacetylase activity. Methods Enzymol. 2004, 377:180-196.
38. Mahlknecht U., Ho A.D., Letzel S., Voelter-Mahlknecht S. Assignment of the NAD-dependent deacetylase sirtuin 5 gene (SIRT5) to human chromosome band 6p23 by in situ hybridization. Cytogenet. Genome Res. 2006, 112:208-212.
39. Lombard D.B., Alt F.W., Cheng H.L., Bunkenborg J., Streeper R.S., Mostoslavsky R., Kim J., Yancopoulos G., Valenzuela D., Murphy A., Yang Y., Chen Y., Hirschey M.D., Bronson R.T., Haigis M., Guarente L.P., Farese R.V., Weissman S., Verdin E., Schwer B. Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol. Cell. Biol. 2007, 27:8807-8814.
40. Schwer B., North B.J., Frye R.A., Ott M., Verdin E. The human silent information regulator (Sir)2 homologue hSIRT3 is a mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase. J. Cell Biol. 2002, 158:647-657.
41. Cooper H.M., Huang J.Y., Verdin E., Spelbrink J.N. A new splice variant of the mouse SIRT3 gene encodes the mitochondrial precursor protein. PLoS One 2009, 4:e4986.
42. +-dependent histone deacetylase that translocates to the mitochondria upon cellular stress. Genes Dev. 2007, 21:920-928.
43. Onyango P., Celic I., McCaffery J.M., Boeke J.D., Feinberg A.P. SIRT3, a human SIR2 homologue, is an NAD-dependent deacetylase localized to mitochondria. Proc. Natl Acad. Sci. USA 2002, 99:13653-13658.
44. Shi T., Wang F., Stieren E., Tong Q. SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes. J. Biol. Chem. 2005, 280:13560-13567.
45. Cooper H.M., Spelbrink J.N. The human Sirt3 protein deacetylase is exclusively mitochondrial. Biochem. J. 2008, 411:279-285.
46. Jin L., Galonek H., Israelian K., Choy W., Morrison M., Xia Y., Wang X., Xu Y., Yang Y., Smith J.J., Hoffmann E., Carney D.P., Perni R.B., Jirousek M.R., Bemis J.E., Milne J.C., Sinclair D.A., Westphal C.H. Biochemical characterization, localization, and tissue distribution of the longer form of mouse SIRT3. Protein Sci. 2009, 18:514-525.
47. Bao J., Lu Z., Joseph J.J., Carabenciov D., Dimond C.C., Pang L., Samsel L., McCoy J.P., Leclerc J., Nguyen P., Gius D., Sack M.N. Characterization of the murine SIRT3 mitochondrial localization sequence and comparison of mitochondrial enrichment and deacetylase activity of long and short SIRT3 isoforms. J. Cell. Biochem. 2010, 110:238-247.
48. Nakamura Y., Ogura M., Tanaka D., Inagaki N. Localization of mouse mitochondrial SIRT proteins: shift of SIRT3 to nucleus by co-expression with SIRT5. Biochem. Biophys. Res. Commun. 2008, 366:174-179.
49. Sundaresan N.R., Samant S.A., Pillai V.B., Rajamohan S.B., Gupta M.P. SIRT3 is a stress responsive deacetylase in cardiomyocytes that protects cells from stress-mediated cell death by deacetylation of Ku-70. Mol. Cell. Biol. 2008, 28:6384-6401.
50. +-dependent protein deacetylase. Biochem. J. 2008, 411:e11-e13.
51. Porcu M., Chiarugi A. The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension. Trends Pharmacol. Sci. 2005, 26:94-103.
52. Lanza I.R., Nair K.S. Mitochondrial function as a determinant of life span. Pflugers Arch. 2010, 459:277-289.
53. Hirschey M.D., Shimazu T., Goetzman E., Jing E., Schwer B., Lombard D.B., Grueter C.A., Harris C., Biddinger S., Ilkayeva O.R., Stevens R.D., Li Y., Saha A.K., Ruderman N.B., Bain J.R., Newgard C.B., Farese R.V., Alt F.W., Kahn C.R., Verdin E. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature 2010, 464:121-125.
54. Ahn B.H., Kim H.S., Song S., Lee I.H., Liu J., Vassilopoulos A., Deng C.X., Finkel T. A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc. Natl Acad. Sci. USA 2008, 105:14447-14452.
55. Yang H., Yang T., Baur J.A., Perez E., Matsui T., Carmona J.J., Lamming D.W., Souza-Pinto N.C., Bohr V.A., Rosenzweig A., de Cabo R., Sauve A.A., Sinclair D.A. Nutrient-sensitive mitochondrial NAD(+) levels dictate cell survival. Cell 2007, 130:1095-1107.
56. Benigni A., Corna D., Zoja C., Sonzogni A., Latini R., Salio M., Conti S., Rottoli D., Longaretti L., Cassis P., Morigi M., Coffman T.M., Remuzzi G. Disruption of the Ang II type 1 receptor promotes longevity in mice. J. Clin. Invest. 2009, 119:524-530.
57. Sundaresan N.R., Gupta M., Kim G., Rajamohan S.B., Isbatan A., Gupta M.P. Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. J. Clin. Invest. 2009, 119:2758-2771.
58. Hafner A.V., Dai J., Gomes A.P., Xiao C.Y., Palmeira C.M., Rosenzweig A., Sinclair D.A. Regulation of the mPTP by SIRT3-mediated deacetylation of CypD at lysine 166 suppresses age-related cardiac hypertrophy. Aging (Albany NY) 2010, 2:914-923.
59. Pillai V.B., Sundaresan N.R., Kim G., Gupta M., Rajamohan S.B., Pillai J.B., Samant S., Ravindra P.V., Isbatan A., Gupta M.P. Exogenous NAD blocks cardiac hypertrophic response via activation of the SIRT3-LKB1-AMP-activated kinase pathway. J. Biol. Chem. 2010, 285:3133-3144.
60. Pillai V.B., Sundaresan N.R., Jeevanandam V., Gupta M.P. Mitochondrial SIRT3 and heart disease. Cardiovasc. Res. 2010, 88:250-256.
61. Qiu X., Brown K., Hirschey M.D., Verdin E., Chen D. Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab. 2010, 12:662-667.
62. Tao R., Coleman M.C., Pennington J.D., Ozden O., Park S.H., Jiang H., Kim H.S., Flynn C.R., Hill S., Hayes McDonald W., Olivier A.K., Spitz D.R., Gius D. Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. Mol. Cell 2010, 40:893-904.
63. Kim S.H., Lu H.F., Alano C.C. Neuronal Sirt3 protects against excitotoxic injury in mouse cortical neuron culture. PLoS One 2011, 6:e14731.
64. Li S., Banck M., Mujtaba S., Zhou M.M., Sugrue M.M., Walsh M.J. p53-Induced growth arrest is regulated by the mitochondrial SirT3 deacetylase. PLoS One 2010, 5:e10486.
65. Alhazzazi T.Y., Kamarajan P., Joo N., Huang J.Y., Verdin E., D'Silva N.J., Kapila Y.L. Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. Cancer 2011, 117:1670-1678.
66. Henson B., Li F., Coatney D.D., Carey T.E., Mitra R.S., Kirkwood K.L., D'Silva N.J. An orthotopic floor-of-mouth model for locoregional growth and spread of human squamous cell carcinoma. J. Oral Pathol. Med. 2007, 36:363-370.
67. Wolter K.G., Wang S.J., Henson B.S., Wang S., Griffith K.A., Kumar B., Chen J., Carey T.E., Bradford C.R., D'Silva N.J. (-)-gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo. Neoplasia 2006, 8:163-172.
68. Sakamoto S., Kyprianou N. Targeting anoikis resistance in prostate cancer metastasis. Mol. Aspects Med. 2010, 31:205-214.
69. Kamarajan P., Bunek J., Lin Y., Nunez G., Kapila Y.L. Receptor-interacting protein shuttles between cell death and survival signaling pathways. Mol. Biol. Cell 2010, 21:481-488.
70. Coates J.M., Galante J.M., Bold R.J. Cancer therapy beyond apoptosis: autophagy and anoikis as mechanisms of cell death. J. Surg. Res. 2010, 164:301-308.
71. Allison S.J., Milner J. SIRT3 is pro-apoptotic and participates in distinct basal apoptotic pathways. Cell Cycle 2007, 6:2669-2677.
72. Ford J., Jiang M., Milner J. Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res. 2005, 65:10457-10463.
73. Pfister J.A., Ma C., Morrison B.E., D'Mello S.R. Opposing effects of sirtuins on neuronal survival: SIRT1-mediated neuroprotection is independent of its deacetylase activity. PLoS One 2008, 3:e4090.
74. Marfe G., Tafani M., Indelicato M., Sinibaldi-Salimei P., Reali V., Pucci B., Fini M., Russo M.A. Kaempferol induces apoptosis in two different cell lines via Akt inactivation, Bax and SIRT3 activation, and mitochondrial dysfunction. J. Cell. Biochem. 2009, 106:643-650.
75. Kim H.S., Patel K., Muldoon-Jacobs K., Bisht K.S., Aykin-Burns N., Pennington J.D., van der Meer R., Nguyen P., Savage J., Owens K.M., Vassilopoulos A., Ozden O., Park S.H., Singh K.K., Abdulkadir S.A., Spitz D.R., Deng C.X., Gius D. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell 2010, 17:41-52.
76. Finley L.W., Carracedo A., Lee J., Souza A., Egia A., Zhang J., Teruya-Feldstein J., Moreira P.I., Cardoso S.M., Clish C.B., Pandolfi P.P., Haigis M.C. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1alpha destabilization. Cancer Cell 2011, 19:416-428.
77. E.L. Bell, B.M. Emerling, S.J. Ricoult, L. Guarente, SirT3 suppresses hypoxia inducible factor 1alpha and tumor growth by inhibiting mitochondrial ROS production, Oncogene. Electronic publication ahead of print.
78. Grubisha O., Rafty L.A., Takanishi C.L., Xu X., Tong L., Perraud A.L., Scharenberg A.M., Denu J.M. Metabolite of SIR2 reaction modulates TRPM2 ion channel. J. Biol. Chem. 2006, 281:14057-14065.
79. Shulga N., Wilson-Smith R., Pastorino J.G. Sirtuin-3 deacetylation of cyclophilin D induces dissociation of hexokinase II from the mitochondria. J. Cell Sci. 2010, 123:894-902.
80. Resendis-Antonio O., Checa A., Encarnacion S. Modeling core metabolism in cancer cells: surveying the topology underlying the Warburg effect. PLoS One 2010, 5. e12383.
81. B.M. Madhok, S. Yeluri, S.L. Perry, T.A. Hughes, D.G. Jayne, Targeting glucose metabolism: an emerging concept for anticancer therapy, Am. J. Clin. Oncol. Electronic publication ahead of print.
82. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
83. Warburg O., Wind F., Negelein E. The metabolism of tumors in the body. J. Gen. Physiol. 1927, 8:519-530.
84. Ferreira L.M. Cancer metabolism: the Warburg effect today. Exp. Mol. Pathol. 2010, 89:372-380.
85. Buzzai M., Bauer D.E., Jones R.G., Deberardinis R.J., Hatzivassiliou G., Elstrom R.L., Thompson C.B. The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. Oncogene 2005, 24:4165-4173.
86. Liu Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis. 2006, 9:230-234.
87. Tsujimoto Y. Apoptosis and necrosis: intracellular ATP level as a determinant for cell death modes. Cell Death Differ. 1997, 4:429-434.
88. Osiewacz H.D. Role of mitochondria in aging and age-related disease. Exp. Gerontol. 2010, 45:465.
89. Verdin E., Hirschey M.D., Finley L.W., Haigis M.C. Sirtuin regulation of mitochondria: energy production, apoptosis, and signaling. Trends Biochem. Sci. 2010, 35:669-675.
90. Tudek B., Winczura A., Janik J., Siomek A., Foksinski M., Olinski R. Involvement of oxidatively damaged DNA and repair in cancer development and aging. Am. J. Transl. Res. 2010, 2:254-284.
91. Cimen H., Han M.J., Yang Y., Tong Q., Koc H., Koc E.C. Regulation of succinate dehydrogenase activity by SIRT3 in mammalian mitochondria. Biochemistry 2010, 49:304-311.
92. Law I.K., Liu L., Xu A., Lam K.S., Vanhoutte P.M., Che C.M., Leung P.T., Wang Y. Identification and characterization of proteins interacting with SIRT1 and SIRT3: implications in the anti-aging and metabolic effects of sirtuins. Proteomics 2009, 9:2444-2456.
93. Schwer B., Bunkenborg J., Verdin R.O., Andersen J.S., Verdin E. Reversible lysine acetylation controls the activity of the mitochondrial enzyme acetyl-CoA synthetase 2. Proc. Natl Acad. Sci. USA 2006, 103:10224-10229.
94. Hallows W.C., Lee S., Denu J.M. Sirtuins deacetylate and activate mammalian acetyl-CoA synthetases. Proc. Natl Acad. Sci. USA 2006, 103:10230-10235.
95. North B.J., Sinclair D.A. Sirtuins: a conserved key unlocking AceCS activity. Trends Biochem. Sci. 2007, 32:1-4.
96. Schlicker C., Gertz M., Papatheodorou P., Kachholz B., Becker C.F., Steegborn C. Substrates and regulation mechanisms for the human mitochondrial sirtuins Sirt3 and Sirt5. J. Mol. Biol. 2008, 382:790-801.
97. Someya S., Yu W., Hallows W.C., Xu J., Vann J.M., Leeuwenburgh C., Tanokura M., Denu J.M., Prolla T.A. Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. Cell 2010, 143:802-812.
98. Yen K.E., Bittinger M.A., Su S.M., Fantin V.R. Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene 2010, 29:6409-6417.
99. Christensen B.C., Smith A.A., Zheng S., Koestler D.C., Houseman E.A., Marsit C.J., Wiemels J.L., Nelson H.H., Karagas M.R., Wrensch M.R., Kelsey K.T., Wiencke J.K. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J. Natl Cancer Inst. 2011, 103:143-153.
100. Zhu J., Zuo J., Xu Q., Wang X., Wang Z., Zhou D. Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients. Med. Hypotheses 2011, 76:602-603.
101. Kong X., Wang R., Xue Y., Liu X., Zhang H., Chen Y., Fang F., Chang Y. Sirtuin 3, a new target of PGC-1alpha, plays an important role in the suppression of ROS and mitochondrial biogenesis. PLoS One 2010, 5:e11707.
102. Zhang W., Della-Fera M.A., Hartzell D.L., Hausman D., Baile C.A. Adipose tissue gene expression profiles in ob/ob mice treated with leptin. Life Sci. 2008, 83:35-42.
103. Shimazu T., Hirschey M.D., Hua L., Dittenhafer-Reed K.E., Schwer B., Lombard D.B., Li Y., Bunkenborg J., Alt F.W., Denu J.M., Jacobson M.P., Verdin E. SIRT3 deacetylates mitochondrial 3-hydroxy-3-methylglutaryl CoA synthase 2 and regulates ketone body production. Cell Metab. 2010, 12:654-661.
104. Probst-Hensch N.M. Chronic age-related diseases share risk factors: do they share pathophysiological mechanisms and why does that matter?. Swiss Med. Wkly 2010, 140:w13072.
105. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
106. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
107. Foulds L. The natural history of cancer. J. Chronic Dis. 1958, 8:2-37.
108. Li D., Ueta E., Kimura T., Yamamoto T., Osaki T. Reactive oxygen species (ROS) control the expression of Bcl-2 family proteins by regulating their phosphorylation and ubiquitination. Cancer Sci. 2004, 95:644-650.
109. Azad N., Iyer A., Vallyathan V., Wang L., Castranova V., Stehlik C., Rojanasakul Y. Role of oxidative/nitrosative stress-mediated Bcl-2 regulation in apoptosis and malignant transformation. Ann. N.Y. Acad. Sci. 2010, 1203:1-6.
110. Azad N., Iyer A.K., Wang L., Lu Y., Medan D., Castranova V., Rojanasakul Y. Nitric oxide-mediated bcl-2 stabilization potentiates malignant transformation of human lung epithelial cells. Am. J. Respir. Cell Mol. Biol. 2010, 42:578-585.
111. Bauer J.A., Kumar B., Cordell K.G., Prince M.E., Tran H.H., Wolf G.T., Chepeha D.B., Teknos T.N., Wang S., Eisbruch A., Tsien C.I., Urba S.G., Worden F.P., Lee J., Griffith K.A., Taylor J.M., D'Silva N., Wang S.J., Wolter K.G., Henson B., Fisher S.G., Carey T.E., Bradford C.R. Targeting apoptosis to overcome cisplatin resistance: a translational study in head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 2007, 69:S106-S108.
112. Stolz C., Hess G., Hahnel P.S., Grabellus F., Hoffarth S., Schmid K.W., Schuler M. Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis. Blood 2008, 112:3312-3321.
113. Duan H., Heckman C.A., Boxer L.M. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol. Cell. Biol. 2005, 25:1608-1619.
114. Chu F., Chou P.M., Zheng X., Mirkin B.L., Rebbaa A. Control of multidrug resistance gene mdr1 and cancer resistance to chemotherapy by the longevity gene sirt1. Cancer Res. 2005, 65:10183-10187.
115. Grenman R., Burk D., Virolainen E., Wagner J.G., Lichter A.S., Carey T.E. Radiosensitivity of head and neck cancer cells in vitro. A 96-well plate clonogenic cell assay for squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 1988, 114:427-431.
116. Carey T.E., Van Dyke D.L., Worsham M.J., Bradford C.R., Babu V.R., Schwartz D.R., Hsu S., Baker S.R. Characterization of human laryngeal primary and metastatic squamous cell carcinoma cell lines UM-SCC-17A and UM-SCC-17B. Cancer Res. 1989, 49:6098-6107.
117. Oberley L.W. Mechanism of the tumor suppressive effect of MnSOD overexpression. Biomed. Pharmacother. 2005, 59:143-148.
118. Ota H., Tokunaga E., Chang K., Hikasa M., Iijima K., Eto M., Kozaki K., Akishita M., Ouchi Y., Kaneki M. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene 2006, 25:176-185.
119. Heltweg B., Gatbonton T., Schuler A.D., Posakony J., Li H., Goehle S., Kollipara R., Depinho R.A., Gu Y., Simon J.A., Bedalov A. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res. 2006, 66:4368-4377.
120. Balcerczyk A., Pirola L. Therapeutic potential of activators and inhibitors of sirtuins. BioFactors 2010, 36:383-393.
121. Signorelli P., Ghidoni R. Resveratrol as an anticancer nutrient: molecular basis, open questions and promises. J. Nutr. Biochem. 2005, 16:449-466.
122. Das D.K., Mukherjee S., Ray D. Resveratrol and red wine, healthy heart and longevity. Heart Fail. Rev. 2010, 15:467-477.
123. Rayalam S., Yang J.Y., Ambati S., Della-Fera M.A., Baile C.A. Resveratrol induces apoptosis and inhibits adipogenesis in 3T3-L1 adipocytes. Phytother. Res. 2008, 22:1367-1371.
124. Mukherjee S., Ray D., Lekli I., Bak I., Tosaki A., Das D.K. Effects of Longevinex (modified resveratrol) on cardioprotection and its mechanisms of action. Can. J. Physiol. Pharmacol. 2010, 88:1017-1025.
125. Dudley J., Das S., Mukherjee S., Das D.K. Resveratrol, a unique phytoalexin present in red wine, delivers either survival signal or death signal to the ischemic myocardium depending on dose. J. Nutr. Biochem. 2009, 20:443-452.
126. Athar M., Back J.H., Tang X., Kim K.H., Kopelovich L., Bickers D.R., Kim A.L. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol. Appl. Pharmacol. 2007, 224:274-283.
127. Bishayee A. Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev. Res. 2009, 2:409-418.
128. Phalon C., Rao D.D., Nemunaitis J. Potential use of RNA interference in cancer therapy. Expert Rev. Mol. Med. 2010, 12:e26.
129. Acharya M.R., Sparreboom A., Venitz J., Figg W.D. Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol. Pharmacol. 2005, 68:917-932.
130. Patel K.R., Scott E., Brown V.A., Gescher A.J., Steward W.P., Brown K. Clinical trials of resveratrol. Ann. N.Y. Acad. Sci. 2011, 1215:161-169.
131. Accessed. http://www.clinicaltrials.gov/ct2/results?term=resveratrol.